Evidence map›Paper›PMID 25315157›Full record

ArticleCancer medicine2015

Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma.

Takahiro Narimatsu, Keiko Matsuura, Chisato Nakada, Yoshiyuki Tsukamoto, Naoki Hijiya, Tomoki Kai, Toru Inoue, Tomohisa Uchida, Takeo Nomura, Fuminori Sato and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. TheGenes · 2018
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Takahiro NarimatsuDepartment of Molecular Pathology, Faculty of Medicine, Oita University, Oita, Japan; Department of Urology, Faculty of Medicine, Oita University, Oita, Japan.
Keiko Matsuura
Chisato Nakada
Yoshiyuki Tsukamoto
Naoki Hijiya
Tomoki Kai
Toru Inoue
Tomohisa Uchida
Takeo Nomura
Fuminori Sato
Masao Seto
Ichiro Takeuchi
Hiromitsu Mimata
Masatsugu Moriyama
Oita University · JPAichi Cancer Center · JPNagoya Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was conducted to clarify the genomic profiles of metastatic clear cell renal cell carcinomas (ccRCCs) and identify the genes responsible for development of metastasis. We analyzed the genomic profiles of 20 cases of primary ccRCC and their corresponding metastases using array-based comparative genomic hybridization, and identified 32 chromosomal regions in which gene copy number alterations were detected more frequently in metastases than in the primary tumors. Among these 32 regions, 9p24.1-p13.3 loss was the most statistically significant alteration. Furthermore, we found that patients with 9p24.1-p13.3 loss in primary tumors exhibited significantly lower rates of recurrence-free and cancer-specific survival, suggesting that 9p loss in the primary tumor is a potential biomarker predicting early recurrence of metastasis. Interestingly, the genomic profiles of primary tumors with 9p loss resembled those of their corresponding metastases, though 9p loss was accumulated in the metastases derived from the primary tumors without 9p loss. Comparison of the mRNA expression levels revealed that 2 of 58 genes located at 9p24.1-p13.3 were downregulated due to gene copy number loss in ccRCCs. An overexpression study of these two genes in ccRCC cell lines revealed that downregulation of NDUFB6 due to loss at 9p24.1-p13.3 may confer a growth advantage on metastatic ccRCC cells. These results were confirmed by analyzing the data of 405 cases of ccRCC obtained from The Cancer Genome Atlas (TCGA). On the basis of our present data, we propose that NDUFB6 is a possible tumor suppressor of metastatic ccRCCs.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 9Gene Expression Regulation, NeoplasticCarcinoma, Renal CellCell Line, TumorCell ProliferationComparative Genomic HybridizationDNA Copy Number VariationsDown-RegulationElectron Transport Complex IHumansKidney NeoplasmsNADH, NADPH OxidoreductasesNeoplasm MetastasisPrognosisReceptors, Cell SurfaceElectron Transport Complex ILRRC19 protein, humanNADH, NADPH OxidoreductasesNDUFB6 protein, humanReceptors, Cell Surface9parray CGHkidney cancermetastasisNDUFB6

Identifiers

PMID25315157
PMCPMC4312125
OpenAlexW2072573480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.